ISS and Glass Lewis Back Evogene’s Board Nominees Ahead of Shareholder Vote
Event summary
- ISS and Glass Lewis recommended Evogene shareholders vote 'FOR' the company’s slate of director nominees ahead of the September 4, 2026, AGM.
- Both firms criticized dissident nominees for lacking a compelling case for board changes.
- Evogene’s board has seen turnover since 2021, with two new directors appointed, including a new chair.
- The company’s nominees include two new directors with relevant experience.
The big picture
Evogene’s proxy advisory wins signal strong shareholder support for its current board strategy amid dissident challenges. The vote outcome will test whether the company can sustain momentum in computational chemistry and generative AI-driven drug and agri-chemical development. The broader biotech sector is watching as governance battles increasingly shape long-term R&D and commercialization strategies.
What we're watching
- Governance Stability
- Whether Evogene can maintain board cohesion and avoid disruptive activism.
- Strategic Execution
- How the current board will advance Evogene’s long-term value creation strategy.
- Shareholder Confidence
- The impact of proxy advisor endorsements on voting outcomes and market perception.
Related topics